Trial
NCT01347645
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eisai Inc.
Collaborators
PharmaBio Development Inc.
Condition
Colon Cancer
Intervention
FOLFIRI
Why stopped
The study was terminated by the Sponsor due to E7820 plus irinotecan being potentially inferior to FOLFIRI
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-22